CN1141297C - 氨氯地平苯磺酸盐的制备方法 - Google Patents

氨氯地平苯磺酸盐的制备方法 Download PDF

Info

Publication number
CN1141297C
CN1141297C CNB998167746A CN99816774A CN1141297C CN 1141297 C CN1141297 C CN 1141297C CN B998167746 A CNB998167746 A CN B998167746A CN 99816774 A CN99816774 A CN 99816774A CN 1141297 C CN1141297 C CN 1141297C
Authority
CN
China
Prior art keywords
methyl
general formula
alkaline earth
quaternary ammonium
alkali metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998167746A
Other languages
English (en)
Chinese (zh)
Other versions
CN1352634A (zh
Inventor
��������ŵʲ
亚诺什·菲舍尔
I
卡塔林·瑟凯
拉斯洛·多贝
山多尔·雷外
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Publication of CN1352634A publication Critical patent/CN1352634A/zh
Application granted granted Critical
Publication of CN1141297C publication Critical patent/CN1141297C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CNB998167746A 1999-07-05 1999-07-05 氨氯地平苯磺酸盐的制备方法 Expired - Lifetime CN1141297C (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/HU1999/000050 WO2001002360A1 (en) 1999-07-05 1999-07-05 Process for preparing amlodipine benzenesulphonate

Publications (2)

Publication Number Publication Date
CN1352634A CN1352634A (zh) 2002-06-05
CN1141297C true CN1141297C (zh) 2004-03-10

Family

ID=10991279

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998167746A Expired - Lifetime CN1141297C (zh) 1999-07-05 1999-07-05 氨氯地平苯磺酸盐的制备方法

Country Status (24)

Country Link
US (1) US6596874B1 (enExample)
EP (1) EP1196383B1 (enExample)
JP (1) JP3764386B2 (enExample)
KR (1) KR100585442B1 (enExample)
CN (1) CN1141297C (enExample)
AT (1) ATE283841T1 (enExample)
AU (1) AU777565B2 (enExample)
BG (1) BG65657B1 (enExample)
CA (1) CA2376540C (enExample)
CZ (1) CZ300509B6 (enExample)
DE (1) DE69922417T2 (enExample)
DK (1) DK1196383T3 (enExample)
EA (1) EA004208B1 (enExample)
EE (1) EE05398B1 (enExample)
ES (1) ES2234272T3 (enExample)
HK (1) HK1044151B (enExample)
MX (1) MXPA01013407A (enExample)
NO (1) NO321714B1 (enExample)
NZ (1) NZ517013A (enExample)
PL (1) PL194193B1 (enExample)
PT (1) PT1196383E (enExample)
SK (1) SK285611B6 (enExample)
UA (1) UA72768C2 (enExample)
WO (1) WO2001002360A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100354806B1 (ko) * 2000-06-21 2002-10-05 한국유나이티드제약 주식회사 암로디핀 베실레이트의 신규 중간체 및 그의 제조방법
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
EP1435954B1 (en) * 2001-07-06 2010-01-13 LEK Pharmaceuticals D.D. A PROCESS FOR THE PREPARATION OF HIGHlLY PUREAMLODIPINE BENZENESULFONATE
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
AR037565A1 (es) * 2001-11-21 2004-11-17 Synthon Bv Formas de sales de amlodipina y procedimientos para prepararlas.
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) * 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
US6784297B2 (en) 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
JP2008013489A (ja) * 2006-07-06 2008-01-24 Ohara Yakuhin Kogyo Kk ベシル酸アムロジピン含有錠剤
EP1975167A1 (en) 2007-03-30 2008-10-01 Esteve Quimica, S.A. Acetone solvate of phthaloyl amlodipine
CN101812014B (zh) * 2010-04-28 2011-08-24 王明 一种苯磺酸氨氯地平化合物及其制法
CN102993083A (zh) * 2012-12-21 2013-03-27 王学军 一种苯磺酸氨氯地平的制备方法
CN104262237A (zh) * 2014-09-28 2015-01-07 常州瑞明药业有限公司 氨氯地平自由碱的合成方法
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
DE19738943B4 (de) 1997-09-05 2008-01-03 Siemens Ag Verfahren und Einrichtung zur Bestimmung von Eigenschaften eines Stahls

Also Published As

Publication number Publication date
SK22002A3 (en) 2002-05-09
AU777565B2 (en) 2004-10-21
ES2234272T3 (es) 2005-06-16
JP3764386B2 (ja) 2006-04-05
PL352493A1 (en) 2003-08-25
MXPA01013407A (es) 2003-09-04
NO20020029L (no) 2002-03-05
UA72768C2 (en) 2005-04-15
EA200200125A1 (ru) 2002-06-27
NO321714B1 (no) 2006-06-26
EP1196383A1 (en) 2002-04-17
HK1044151B (zh) 2004-09-10
EP1196383B1 (en) 2004-12-01
NO20020029D0 (no) 2002-01-04
US6596874B1 (en) 2003-07-22
WO2001002360A1 (en) 2001-01-11
EA004208B1 (ru) 2004-02-26
NZ517013A (en) 2003-08-29
AU4923799A (en) 2001-01-22
ATE283841T1 (de) 2004-12-15
CN1352634A (zh) 2002-06-05
BG65657B1 (bg) 2009-05-29
EE05398B1 (et) 2011-04-15
CA2376540C (en) 2007-03-13
DE69922417T2 (de) 2005-12-01
KR100585442B1 (ko) 2006-06-02
EE200100686A (et) 2003-04-15
HK1044151A1 (en) 2002-10-11
KR20020022760A (ko) 2002-03-27
SK285611B6 (sk) 2007-04-05
BG106164A (en) 2002-07-31
DE69922417D1 (de) 2005-01-05
CZ20014690A3 (cs) 2002-04-17
DK1196383T3 (da) 2005-02-21
PL194193B1 (pl) 2007-05-31
CZ300509B6 (cs) 2009-06-03
PT1196383E (pt) 2005-03-31
JP2003503477A (ja) 2003-01-28
CA2376540A1 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
CN1141297C (zh) 氨氯地平苯磺酸盐的制备方法
US5354760A (en) Crystalline Tiagabine monohydrate, its preparation and use
JP2995704B2 (ja) 光学活性な１ｈ−３−アミノピロリジン化合物の製造法
PL191995B1 (pl) Sposób otrzymywania soli kwasu benzenosulfonowego 3-etylo-5-metylo-2-(2-aminoetoksymetylo)-4-(2-chlorofenylo)-6-metylo-1,4-dihydropirydyno-3,5-dikarboksylanu oraz związki przejściowe
EP1438291B1 (fr) Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant
JP2668570B2 (ja) 化合物の新規な製造方法
JPH0521105B2 (enExample)
WO2005023769A1 (en) Process for the preparation of amlodipine salts
EP1891009B1 (en) A novel process for the preparation of lercanidipine
KR100469030B1 (ko) 시사프라이드의 합성방법
KR100374405B1 (ko) 암로디핀 베실레이트의 제조방법
JP3202120B2 (ja) １，４−ジヒドロピリジン誘導体及びそれを用いる１，４−ジヒドロピリジンカルボン酸誘導体の製造方法
JP2002533431A (ja) １−（アミノメチル）シクロヘキシル酢酸の合成方法
WO2006090265A2 (en) Processes for the preparation of levetiracetam, its intermediate and the use of levetiracetam in pharmaceutical compositions
JP4441260B2 (ja) ４−アミノ−４−フェニルピペリジン類の製造方法
CN101490009B (zh) 用作p物质拮抗剂的酰基氨基亚烯基酰胺的合成
JP3013760B2 (ja) ４−ヒドロキシ−２−ピロリドンの製法
JPH08217749A (ja) 塩酸ニカルジピンの新規製造法及び新規合成中間体
JP2010526126A (ja) バルサルタンの製造方法
JPH033663B2 (enExample)
JPH1180151A (ja) オキセパン−２−オン誘導体の製造方法

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20040310

CX01 Expiry of patent term